Annals of internal medicine · 2019 · DOI
This study tested whether rituximab, a medication that reduces certain immune cells, could help patients with ME/CFS. Researchers gave some patients rituximab and others a placebo (fake treatment) to see if it would improve their symptoms and ability to function. This was one of the first major clinical trials to test this specific treatment in ME/CFS patients.
This trial represents an important investigation into whether immune-modulating therapy can treat ME/CFS, a condition where no FDA-approved treatments exist. If rituximab showed benefit, it could offer a targeted therapy option and support the immune dysfunction theory of ME/CFS. Even negative or mixed results provide valuable evidence to guide future research directions.
This study does not prove that B-cell dysfunction is the sole cause of ME/CFS, only that targeting B cells may or may not improve symptoms in some patients. A single trial cannot establish long-term safety or determine which patient subgroups might benefit most from rituximab. Results from one study also do not rule out the need for combination therapies or alternative treatment approaches.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Unknown authors (2019). Rituximab for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.. Annals of internal medicine. https://doi.org/10.7326/P19-0004
BibTeX
@article{mecfsatlas-unknown-2019-rituximab-patients,
author = {Unknown, Author},
title = {Rituximab for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {Annals of internal medicine},
year = {2019},
doi = {10.7326/P19-0004},
note = {PubMed: 30934061},
url = {https://www.mecfsatlas.com/evidence/unknown-2019-rituximab-patients},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-28. https://www.mecfsatlas.com/evidence/unknown-2019-rituximab-patients
Contribute
Private, reviewed by a human. Not a public comment thread.